JP2012501351A5 - - Google Patents

Download PDF

Info

Publication number
JP2012501351A5
JP2012501351A5 JP2011525283A JP2011525283A JP2012501351A5 JP 2012501351 A5 JP2012501351 A5 JP 2012501351A5 JP 2011525283 A JP2011525283 A JP 2011525283A JP 2011525283 A JP2011525283 A JP 2011525283A JP 2012501351 A5 JP2012501351 A5 JP 2012501351A5
Authority
JP
Japan
Prior art keywords
key
type
site
composition
vaccine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2011525283A
Other languages
English (en)
Japanese (ja)
Other versions
JP2012501351A (ja
JP5707326B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2009/055608 external-priority patent/WO2010027973A1/en
Publication of JP2012501351A publication Critical patent/JP2012501351A/ja
Publication of JP2012501351A5 publication Critical patent/JP2012501351A5/ja
Application granted granted Critical
Publication of JP5707326B2 publication Critical patent/JP5707326B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2011525283A 2008-09-02 2009-09-01 ヒトパピローマウイルス／Ｉｉ−ｋｅｙのハイブリッドおよびその使用方法 Expired - Fee Related JP5707326B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US9360608P 2008-09-02 2008-09-02
US61/093,606 2008-09-02
US16990809P 2009-04-16 2009-04-16
US61/169,908 2009-04-16
PCT/US2009/055608 WO2010027973A1 (en) 2008-09-02 2009-09-01 Human papillomavirus / li-key hybrids and methods of use

Publications (3)

Publication Number Publication Date
JP2012501351A JP2012501351A (ja) 2012-01-19
JP2012501351A5 true JP2012501351A5 (enExample) 2012-10-18
JP5707326B2 JP5707326B2 (ja) 2015-04-30

Family

ID=41797447

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2011525283A Expired - Fee Related JP5707326B2 (ja) 2008-09-02 2009-09-01 ヒトパピローマウイルス／Ｉｉ−ｋｅｙのハイブリッドおよびその使用方法

Country Status (5)

Country Link
US (1) US8748130B2 (enExample)
EP (1) EP2344191A4 (enExample)
JP (1) JP5707326B2 (enExample)
CA (1) CA2731444A1 (enExample)
WO (1) WO2010027973A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI2865387T1 (sl) * 2008-11-21 2019-10-30 Kobenhavns Univ University Of Copenhagen Primiranje imunskega odziva
EP2883550A1 (en) * 2013-12-12 2015-06-17 Deutsches Krebsforschungszentrum Stiftung des Öffentlichen Rechts Novel promiscuous HPV16-derived T helper epitopes for immunotherapy
CA3066779A1 (en) * 2017-06-28 2019-01-03 Regeneron Pharmaceuticals, Inc. Anti-human papillomavirus (hpv) antigen-binding proteins and methods of use thereof
CN112218883A (zh) * 2018-04-26 2021-01-12 艾吉纳斯公司 热休克蛋白结合肽组合物及其使用方法

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU671623B2 (en) * 1992-03-06 1996-09-05 N.V. Innogenetics S.A. Process for the determination of peptides corresponding to immunologically important epitopes and biotinylated peptides used therein
AU5670194A (en) 1992-11-20 1994-06-22 Enzon, Inc. Linker for linked fusion polypeptides
US5559028A (en) 1993-05-19 1996-09-24 Antigen Express, Inc. Methods of enhancing or antigen presentation to T cells inhibiting
US5910300A (en) 1995-11-01 1999-06-08 Bracco Research S.A. Amphiphilic linkers for coupling administrable diagnostically or physiologically active agents and bioselective targeting compounds
AU3307497A (en) 1996-06-26 1998-01-14 Antigen Express, Inc. Immunotherapy by modulation of antigen presentation
US6432409B1 (en) * 1999-09-14 2002-08-13 Antigen Express, Inc. Hybrid peptides modulate the immune response
US7026443B1 (en) * 1999-12-10 2006-04-11 Epimmune Inc. Inducing cellular immune responses to human Papillomavirus using peptide and nucleic acid compositions
US7179645B2 (en) 2002-09-24 2007-02-20 Antigen Express, Inc. Ii-Key/antigenic epitope hybrid peptide vaccines
ATE465753T1 (de) * 2002-10-21 2010-05-15 Eisai Inc Zusammensetzungen und verfahren zurbehandlung von krankheiten, die durch das humane papillomavirus vermitteltwerden
US20080095798A1 (en) * 2006-10-18 2008-04-24 Robert Humphreys Ii-key enhanced vaccine potency
MX2009012922A (es) * 2007-05-31 2010-07-05 Academisch Ziekenhuis Leiden H Vacunacion intradermica de un peptido del virus del papiloma humano.
US7750588B2 (en) 2007-06-29 2010-07-06 Faurecia Automotive Seating Canada Limited Method of counting drive motor rotations, and memory modules, storage media, and motor and vehicle apparatuses utilizing same

Similar Documents

Publication Publication Date Title
CN111217917B (zh) 一种新型冠状病毒SARS-CoV-2疫苗及其制备方法
JP2008529558A5 (enExample)
JP2013501038A5 (enExample)
JP2015509707A5 (enExample)
EP3463444B1 (en) Improvement of hpv l2 peptide immunogenicity
JP2010529860A5 (enExample)
JP2019506175A5 (enExample)
JP2008505985A5 (enExample)
JP2012515557A5 (enExample)
US20250222094A1 (en) Polynucleotide molecules used for the prevention or treatment of hpv infection related diseases
JP2012516140A5 (enExample)
JP2010506926A5 (enExample)
CN101952320B (zh) 具有免疫原性的物质
JP2012501351A5 (enExample)
JP2005512518A5 (enExample)
JP2008539164A5 (enExample)
CN113430178B (zh) 一种表达ii型单纯疱疹病毒蛋白的重组流感病毒株及其制备方法与应用
JP2011521648A5 (enExample)
JP2002516662A5 (enExample)
CN101880328A (zh) 微小隐孢子虫Th多表位基因和融合蛋白及其应用
AU2018342997B2 (en) Cutaneous papilloma virus vaccine
US20210228702A1 (en) Combined prophylactic and therapeutic vaccines
JP2014503174A5 (enExample)
JPWO2023034783A5 (enExample)
HK40006519B (en) Improvement of hpv l2 peptide immunogenicity